Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders | Zendy

Peter Humaidan | Zendy; Wai Chin | Zendy; Daniela Rogoff | Zendy; Thomas D’Hooghe | Zendy; S. Longobardi | Zendy; Julie Hubbard | Zendy; Joan Schertz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders

Author(s) -

Peter Humaidan,

Wai Chin,

Daniela Rogoff,

Thomas D’Hooghe,

S. Longobardi,

Julie Hubbard,

Joan Schertz

Publication year - 2017

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dew360

Subject(s) - ovarian hyperstimulation syndrome , medicine , clinical endpoint , randomized controlled trial , adverse effect , menotropins , gynecology , ovulation induction , ovarian reserve , randomization , in vitro fertilisation , infertility , pregnancy , hormone , biology , ovulation , genetics

How does the efficacy and safety of a fixed-ratio combination of recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH) compare with that of r-hFSH monotherapy for controlled ovarian stimulation (COS) in patients with poor ovarian response (POR)?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research